AR114237A1 - Compuesto de amida heterocíclica que contiene nitrógeno y su uso farmacéutico - Google Patents

Compuesto de amida heterocíclica que contiene nitrógeno y su uso farmacéutico

Info

Publication number
AR114237A1
AR114237A1 ARP190100202A ARP190100202A AR114237A1 AR 114237 A1 AR114237 A1 AR 114237A1 AR P190100202 A ARP190100202 A AR P190100202A AR P190100202 A ARP190100202 A AR P190100202A AR 114237 A1 AR114237 A1 AR 114237A1
Authority
AR
Argentina
Prior art keywords
alkyl
independently selected
nitrogen atom
group
atom
Prior art date
Application number
ARP190100202A
Other languages
English (en)
Inventor
Nobutaka Yamaoka
Dai Motoda
Ritsuki Masuo
Masayuki Kotoku
Koichi Suzawa
Takaki Maeba
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of AR114237A1 publication Critical patent/AR114237A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)

Abstract

La presente proporciona un compuesto que tiene actividad inhibitoria de PDHK y útil para el tratamiento o profilaxis de diabetes (diabetes tipo 1, diabetes tipo 2, etc.), síndrome de resistencia a la insulina, síndrome metabólico, hiperglucemia, hiperlactacidemia, complicación diabéticas (neuropatía diabética, retinopatía diabética, nefropatía diabética, catarata etc.), insuficiencia cardíaca (insuficiencia cardíaca aguda, insuficiencia cardíaca crónica), cardiomiopatía, isquemia miocárdica, infarto de miocardio, angina de pecho, dislipidemia, aterosclerosis, enfermedad arterial periférica, claudicación intermitente, enfermedad pulmonar obstructiva crónica, isquemia cerebral, apoplejía cerebral, enfermedad mitocondrial, encefalomiopatía mitocondrial, cáncer, hipertensión pulmonar o enfermedad de Alzheimer. La presente se refiere a un compuesto de la fórmula [1] o la fórmula [2], o una de sus sales farmacéuticamente aceptables, donde cada símbolo significa lo mismo como se describe en la memoria descriptiva. Reivindicación 1: Un compuesto de la fórmula [1] o la fórmula [2], o una de sus sales farmacéuticamente aceptables, caracterizado porque un enlace en una línea de puntos es un enlace simple o un enlace doble; X¹ es un átomo de carbono, un átomo de nitrógeno o un átomo de oxígeno; X² es un átomo de carbono o un átomo de nitrógeno; R¹ᵃ es alquilo C₁₋₄ o alquilo C₁₋₄carbonilo; R² es halógeno, ciano o alquilo C₁₋₄; m es 0 ó 1; n es 0, 1 ó 2, cuando n es 2, cada R² es el mismo o diferente; A¹, A², A³, A⁴, A⁵, A⁶ y A⁷ se seleccionan de modo independiente de un átomo de carbono, un átomo de nitrógeno y un átomo de oxígeno; A⁸ se selecciona de un átomo de carbono y un átomo de nitrógeno, y un número total del átomo de nitrógeno y el átomo de oxígeno contenido en una fórmula estructural parcial [3] es 0, 1, 2 ó 3; t es 0 ó 1; r es 0, 1 ó 2, y un total de t y r es 1 ó 2; w es 0 ó 1; R³ y R⁴ son cada uno de modo independiente hidrógeno o alquilo C₁₋₄; Cy¹ es (1) (i) cicloalquilo C₄₋₆; o (ii) heterociclilo saturado o parcialmente saturado de 4 a 6 miembros que tiene un átomo de nitrógeno, el cicloalquilo C₄₋₆ y el heterociclilo saturado o parcialmente saturado está opcionalmente sustituido con un sustituyente seleccionado de modo independiente del grupo que consiste en alquilo C₁₋₄ y oxo, o (2) (i) fenilo o (ii) heteroarilo de 5 ó 6 miembros que tiene 1, 2 ó 3 heteroátomos seleccionados de modo independiente del grupo que consiste en un átomo de nitrógeno y un átomo de oxígeno, el fenilo y el heteroarilo están opcionalmente sustituidos con 1 ó 2 sustituyentes seleccionados de modo independiente del grupo que consiste en halógeno, ciano, carboxi, alquilo C₁₋₄, haloalquilo C₁₋₄ y cicloalquilo C₃₋₆; Cy² es (1) (i) cicloalquilo C₃₋₆ o (ii) heterociclilo saturado de 4 a 6 miembros que tiene 1 ó 2 heteroátomos seleccionados de modo independiente del grupo que consiste en un átomo de nitrógeno y un átomo de oxígeno, y el cicloalquilo C₃₋₆ y el heterociclilo saturado están opcionalmente sustituidos con 1 ó 2 sustituyentes seleccionados de modo independiente del grupo que consiste en halógeno, hidroxi y alquilo C₁₋₄, o (2) (i) fenilo o (ii) heteroarilo de 5 ó 6 miembros que tiene 1, 2, 3 ó 4 átomos de nitrógeno, y el fenilo y el heteroarilo están opcionalmente sustituidos con 1 ó 2 sustituyentes seleccionados de modo independiente del grupo que consiste en halógeno, ciano, alquilo C₁₋₄, alcoxi C₁₋₄; y alquilo C₁₋₄sulfonilo; y v es 0 ó 1.
ARP190100202A 2018-02-01 2019-01-30 Compuesto de amida heterocíclica que contiene nitrógeno y su uso farmacéutico AR114237A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018016328 2018-02-01

Publications (1)

Publication Number Publication Date
AR114237A1 true AR114237A1 (es) 2020-08-05

Family

ID=67479787

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100202A AR114237A1 (es) 2018-02-01 2019-01-30 Compuesto de amida heterocíclica que contiene nitrógeno y su uso farmacéutico

Country Status (20)

Country Link
US (2) US10800784B2 (es)
EP (1) EP3747888A4 (es)
JP (2) JP7241556B2 (es)
KR (1) KR20200115566A (es)
CN (1) CN111655692B (es)
AR (1) AR114237A1 (es)
AU (1) AU2019214048B2 (es)
BR (1) BR112020014177A2 (es)
CA (1) CA3090219A1 (es)
CL (1) CL2020002003A1 (es)
CO (1) CO2020009420A2 (es)
IL (1) IL276386B2 (es)
MX (1) MX2020008126A (es)
PE (1) PE20211273A1 (es)
PH (1) PH12020500613A1 (es)
SA (1) SA520412473B1 (es)
SG (1) SG11202006916SA (es)
TW (1) TWI803570B (es)
WO (1) WO2019151274A1 (es)
ZA (1) ZA202004548B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112638377A (zh) 2018-09-11 2021-04-09 日本烟草产业株式会社 含有吡唑酰胺化合物的慢性肾脏病的治疗或预防剂
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
IL295281A (en) 2020-02-07 2022-10-01 Gasherbrum Bio Inc Heterocyclic glp-1 agonists
CA3166747A1 (en) * 2020-03-04 2021-09-10 Japan Tobacco Inc. Fused tricyclic compound and medicinal use thereof
JP2023540609A (ja) * 2020-09-10 2023-09-25 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
WO2023032940A1 (ja) 2021-09-01 2023-03-09 日本たばこ産業株式会社 含窒素三環性化合物及びその医薬用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943617B2 (en) * 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
WO2008132162A1 (en) * 2007-04-26 2008-11-06 Boehringer Ingelheim International Gmbh 3- (sulphonylamino) -phenyl-2 -hydroxy-ethylamino derivatives useful as beta-agonists, processes for preparing them and their use as medicaments
PE20090319A1 (es) * 2007-06-01 2009-03-27 Schering Corp Moduladores de gamma secretasa
EP2090576A1 (en) * 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
AR074797A1 (es) * 2008-10-10 2011-02-16 Japan Tobacco Inc Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
BR112013033098B8 (pt) 2011-06-27 2021-03-23 Alectos Therapeutics Inc inibidores de glicosidade seletivos e usos dos mesmos
WO2013074388A1 (en) * 2011-11-15 2013-05-23 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as gpr119 agonists
NZ630488A (en) 2012-06-12 2016-07-29 Chong Kun Dang Pharm Corp Piperidine derivatives for gpr119 agonist
CN103570725B (zh) 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
NO2975028T3 (es) * 2013-03-15 2018-07-21
WO2015002119A1 (ja) 2013-07-01 2015-01-08 日本たばこ産業株式会社 ピラゾール－アルコール化合物およびその医薬用途
TW201536748A (zh) * 2013-07-01 2015-10-01 Japan Tobacco Inc 茀－醯胺化合物及其醫藥用途
GB201316823D0 (en) 2013-09-23 2013-11-06 R & D Vernalis Ltd New Chemical Entities
JP6527520B2 (ja) 2013-12-17 2019-06-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ピルビン酸脱水素酵素キナーゼの阻害剤としてのｎ１−（３，３，３−トリフルオロ−２−ヒドロキソ−２−メチルプロピオニル）−ピペリジン誘導体
WO2017020981A1 (en) 2015-07-31 2017-02-09 Merck Patent Gmbh Bicyclic heterocyclic derivatives
JP6923551B2 (ja) 2016-03-29 2021-08-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ピルバートデヒドロゲナーゼキナーゼのインヒビターとしてのｎ１−（３，３，３−トリフルオロ−２−ヒドロキシ−２−メチルプロピオニル）−ピペリジン誘導体
JP7028792B2 (ja) * 2016-04-28 2022-03-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ピペリジニル誘導体
RU2736722C2 (ru) * 2016-07-29 2020-11-19 Джапан Тобакко Инк. Способ получения соединения пиразоламида
US10414774B2 (en) 2016-08-15 2019-09-17 Merck Sharp & Dohme Corp. Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease
BR112018013247A2 (pt) 2016-10-28 2018-12-04 H Lundbeck As tratamentos de combinação compreendendo imidazopirazinonas para o tratamento de distúrbios psiquiátricos e/ou cognitivos
EP3532053A1 (en) 2016-10-28 2019-09-04 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
CA3166747A1 (en) * 2020-03-04 2021-09-10 Japan Tobacco Inc. Fused tricyclic compound and medicinal use thereof
WO2023032940A1 (ja) * 2021-09-01 2023-03-09 日本たばこ産業株式会社 含窒素三環性化合物及びその医薬用途

Also Published As

Publication number Publication date
MX2020008126A (es) 2020-09-18
EP3747888A1 (en) 2020-12-09
US20200017505A1 (en) 2020-01-16
JP2023071925A (ja) 2023-05-23
CO2020009420A2 (es) 2020-08-10
JP2019131544A (ja) 2019-08-08
SG11202006916SA (en) 2020-08-28
RU2020128593A (ru) 2022-03-03
US10800784B2 (en) 2020-10-13
CN111655692A (zh) 2020-09-11
TW201934553A (zh) 2019-09-01
EP3747888A4 (en) 2021-12-15
AU2019214048A1 (en) 2020-06-25
AU2019214048B2 (en) 2023-03-16
ZA202004548B (en) 2021-10-27
CL2020002003A1 (es) 2020-10-23
PE20211273A1 (es) 2021-07-19
CN111655692B (zh) 2023-10-10
IL276386B2 (en) 2023-06-01
IL276386A (en) 2020-09-30
SA520412473B1 (ar) 2023-02-12
US20210284644A1 (en) 2021-09-16
KR20200115566A (ko) 2020-10-07
JP7241556B2 (ja) 2023-03-17
BR112020014177A2 (pt) 2020-12-08
WO2019151274A1 (ja) 2019-08-08
TWI803570B (zh) 2023-06-01
PH12020500613A1 (en) 2021-05-31
CA3090219A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
AR114237A1 (es) Compuesto de amida heterocíclica que contiene nitrógeno y su uso farmacéutico
AR100645A1 (es) Derivados de pirazolo-pirimidina
AR120183A1 (es) Compuestos de heteroaril-pirazina como plaguicidas
AR108745A1 (es) Derivados de oxadiazol microbiocidas
PE20130010A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina como inhibidor de la integrasa del vih
PE20181269A1 (es) Agonistas del receptor de apelina y metodos de uso
AR069517A1 (es) Compuesto del acido fenil metiloxifenil piridinil carboxilico substituido, composiciones farmaceuticas que lo comprenden y su uso para la prepara-cion de un medicamento util para el tratamiento de una enfermedad mediada por la actividad de la enzima sgc
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos
PE20091972A1 (es) Compuestos heterociclicos como inhibidores del factor ixa
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
AR083872A1 (es) Derivados de acido carbamoil-cicloalquil-acetico sustituidos como inhibidores de nep
AR106778A1 (es) Derivados heterocíclicos activos como plaguicidas con sustituyentes que contienen azufre y ciclopropilo
AR064824A1 (es) Derivados de espirocromanona sustituidos
PE20161064A1 (es) Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo
CL2018000697A1 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue.
PE20200724A1 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
UY31616A1 (es) Derivados de urea de tetrahidroquinoxalina, su preparación y su aplicación en terapéutica
CO6270225A2 (es) Un compuesto novedoso de anillo fusionado que presenta actividad inhibitoria de faah
PE20160523A1 (es) Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis
AR118706A2 (es) Compuesto para el control de plagas y vegetación no deseada, procedimiento para prepararlo, composición que lo comprende, y compuesto intermediario relacionado
AR075534A1 (es) Derivados de piridazinona sustituida por heteroarilo
BR112012017474A2 (pt) composto, sal farmacologicamente aceitável do composto, droga farmacêutica, inibidor da fibrinólise ativável por trombina, promotor da fibrinólise, droga preventiva ou terapêutica, composição farmacêutica, uso de uma composição farmacêutica, inibidor de tafia para injeção, e, uso de uma composição farmacêutica
AR111199A1 (es) Compuesto aromático agonista de gpr40
PE20171443A1 (es) Derivados de carboxamida
AR080969A1 (es) Compuesto biciclico